Aton Pharma Introduces Expanded Distribution of Lacrisert(R) (hydroxypropyl cellulose ophthalmic insert) at Ha...(l cellulose. If improperly placedLacrise...)

Lacrisert, as demonstrated in several clinical studies, can help to alleviate symptoms in moderate to severe dry eye patients who may not be receiving adequate relief from artificial tears or who may use preserved tears too often. In a study comparing Lacrisert once-daily with artificial tears used at least 4 times a day, Lacrisert was more effective at relieving symptoms and was able to help existing tears stay longer on the eye surface. Most patients in clinical studies preferred Lacrisert over artificial tears. Lacrisert has also been shown to be effective in patients with Sjogren's syndrome. There are no known interactions with other eye medications.

About Aton Pharma, Inc.

Aton Pharma, Inc., headquartered in Lawrenceville, NJ, is a global specialty pharmaceutical company providing essential treatments for under- treated diseases including chronic moderate to severe dry eye, to patients around the world. Aton's mission is to improve patient outcomes and quality of life worldwide by enhancing and expanding access and availability of medically essential therapeutics. Aton's portfolio of seven products, with sales in 32 countries, targets rare and orphan metabolic, neurological, cardiovascular and ophthalmic diseases. For more information, see http://www.atonrx.com.

*Some patients may require the flexibility of twice-daily dosing for optimal results.

CONTACT: Ed Stevens, 727-327-3396, Estevens3@tampabay.rr.co